Literature DB >> 27281399

Amgen/UCB build on bone franchise with anti-sclerostin antibody.

Suzanne Elvidge.   

Abstract

Year:  2016        PMID： 27281399     DOI： 10.1038/nbt0616-580b

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  4 in total

1.  Can 'double blockbuster' strengthen Amgen's backbone?

Authors:  Cormac Sheridan
Journal:  Nat Biotechnol       Date:  2008-04       Impact factor: 54.908

2.  Sclerostin inhibition promotes TNF-dependent inflammatory joint destruction.

Authors:  Corinna Wehmeyer; Svetlana Frank; Denise Beckmann; Martin Böttcher; Christoph Cromme; Ulrich König; Michelle Fennen; Annelena Held; Peter Paruzel; Christine Hartmann; Athanasios Stratis; Adelheid Korb-Pap; Thomas Kamradt; Ina Kramer; Wim van den Berg; Michaela Kneissel; Thomas Pap; Berno Dankbar
Journal:  Sci Transl Med       Date:  2016-03-16       Impact factor: 17.956

3.  Osteopetrosis with syndactyly; a morphological variant of Albers-Schönberg's disease.

Authors:  A S TRUSWELL
Journal:  J Bone Joint Surg Br       Date:  1958-05

4.  Do bisphosphonates affect bone healing? A meta-analysis of randomized controlled trials.

Authors:  Deting Xue; Fangcai Li; Gang Chen; Shigui Yan; Zhijun Pan
Journal:  J Orthop Surg Res       Date:  2014-06-05       Impact factor: 2.359
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.